Winter Park, Florida — November 24, 2025 — Leads & Copy — ADIA Nutrition, Inc. (OTCQB: ADIA) has announced the submission of its complete, patent-pending regenerative protocol for pediatric Autism Spectrum Disorder (ASD) to an independent Institutional Review Board (IRB) for full review and potential acceptance of oversight.
The submission marks a pivotal milestone, as the full protocol, which includes detailed methodology, rigorous safety measures, dosing regimen, and clinical endpoints, is now under expert evaluation. If accepted, the IRB would immediately authorize ADIA’s first IRB-approved human study using antioxidants and stem cells in children with ASD.
Larry Powalisz, CEO of ADIA Nutrition, stated that the IRB now has everything they need to approve their work and that acceptance would open the door to more IRBs and fast-track credible, life-changing data for families, as well as explosive value for shareholders.
Shareholders will receive updates throughout the process, with the next announcement expected upon IRB determination.
The protocol will remain confidential while intellectual property and clinical pathways advance in parallel.
ADIA Nutrition Inc. specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. It is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair.
Adia Med clinics also offer specialized regenerative treatments such as stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services. Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. The company also invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company.
ADIA Nutrition Inc. aims to advance healthcare through innovation, bold partnerships with top-tier medical entities, and a commitment to standardized, FDA-approved lab protocols.
Larry Powalisz can be contacted at ceo@adiamed.com or by phone at 321-788-0850.
Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia’s regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed.
Source: ADIA Nutrition, Inc.
